Leerink Partnrs Issues Optimistic Estimate for LENZ Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Equities researchers at Leerink Partnrs raised their Q4 2024 EPS estimates for shares of LENZ Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings of ($0.39) per share for the quarter, up from their previous estimate of ($0.52). The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.09) per share. Leerink Partnrs also issued estimates for LENZ Therapeutics' FY2025 earnings at ($2.40) EPS, FY2026 earnings at ($2.55) EPS and FY2028 earnings at $1.25 EPS.

Several other research analysts have also commented on LENZ. Raymond James initiated coverage on shares of LENZ Therapeutics in a research note on Friday, September 27th. They set an "outperform" rating and a $37.00 price objective for the company. William Blair upgraded shares of LENZ Therapeutics to a "strong-buy" rating in a research note on Friday, August 30th. Piper Sandler restated an "overweight" rating and set a $36.00 price target on shares of LENZ Therapeutics in a research note on Thursday, August 15th. Finally, HC Wainwright restated a "buy" rating and set a $38.00 price target on shares of LENZ Therapeutics in a research note on Thursday. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $35.40.

LENZ Therapeutics Trading Up 1.9 %

Shares of NASDAQ:LENZ traded up $0.68 during trading hours on Monday, hitting $35.75. The company's stock had a trading volume of 184,455 shares, compared to its average volume of 136,713. The firm's fifty day moving average price is $24.94 and its 200 day moving average price is $21.27. LENZ Therapeutics has a 52 week low of $14.07 and a 52 week high of $37.13.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.09. During the same quarter in the prior year, the business posted ($1.33) earnings per share.

Hedge Funds Weigh In On LENZ Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of LENZ. American International Group Inc. purchased a new position in LENZ Therapeutics during the first quarter worth about $44,000. SG Americas Securities LLC acquired a new stake in shares of LENZ Therapeutics during the third quarter valued at about $107,000. GSA Capital Partners LLP acquired a new stake in shares of LENZ Therapeutics during the third quarter valued at about $246,000. Squarepoint Ops LLC acquired a new stake in shares of LENZ Therapeutics during the second quarter valued at about $181,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of LENZ Therapeutics during the first quarter valued at about $362,000. 54.32% of the stock is owned by hedge funds and other institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.